We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel, High-Accuracy Blood Test Can Screen for Multiple Cancers

By LabMedica International staff writers
Posted on 26 Nov 2019
A new targeted methylation-based assay has been developed that is able to screen blood samples for more than 20 types of cancer at all stages, including lung cancer, with high accuracy and it also correctly pinpoints the tissue of origin (TOO).

Methylation works to activate or deactivate genes, and altered methylation suggests cancer. More...
Besides lung cancer, the methylation-based assay screens for anal, bladder, colorectal, esophageal, head and neck, liver/bile duct, lymphoma, ovarian, pancreatic, plasma cell neoplasm, and stomach cancers, among others. Methylation works to activate or deactivate genes, and altered methylation suggests cancer.

Scientists from the Dana-Farber Cancer Institute (Boston, MA, USA) and their colleagues in a prospective study colleagues analyzed cell-free DNA (cfDNA), DNA that is released into the bloodstream following cell death, in 3,583 blood samples, of which 1,530 were from patients with cancer and 2,053 were from cancer-free individuals. The assay functions by quantifying abnormal methylation patterns in cfDNA, whereas liquid biopsies isolate genetic mutations or other types of DNA alterations.

The team reported that the overall specificity of the assay was 99.4%, and the sensitivity for aggressive cancers was 76%. Specifically, sensitivity was 32% in stage I cancer, 76% in stage II cancer, 85% in stage III cancer, and 93% in stage IV cancer. In all cancer types, sensitivity was 55%. The scientists also noted that 97% of samples yielded TOO results, with correct TOO recorded in 89% of samples. For diagnosing non-small cell lung cancer (NSCLC), biopsy is currently the gold standard, while molecular testing is used to shed light on treatment options in advanced-stage or even early-stage NSCLC.

The scientists stated that in many types of cancer, methylation is better reflective of cancer diagnosis than are other types of mutations. Indeed, they had previously found that whole-genome bisulfite sequencing (i.e., the methylation assay) outperformed whole-genome and targeted-sequencing strategies in detecting cancer. Ultimately, if this new methylation-based assay was to pick up even a small number of early-stage cancer types, many patients would benefit from earlier treatment.

Geoffrey R. Oxnard, MD, a medical oncologist and lead author of the study, said, “Our previous work indicated that methylation-based assays outperform traditional DNA-sequencing approaches to detecting multiple forms of cancer in blood samples. The results of the new study demonstrate that such assays are a feasible way of screening people for cancer.” The study was presented at the European Society for Medical Oncology Congress, (ESMO), held in September 27–October 1, 2019, in Barcelona, Spain.

Related Links:
Dana-Farber Cancer Institute


New
Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.